Quick Answer
Vaxcyte, Inc. reported Common Stock Shares Outstanding of 131.06 million shares for the year ending 2025.
- Vaxcyte, Inc. showed an increase of +4.9% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: 50.88 million shares | Q3 2020: 50.95 million shares | Q1 2021: 51.34 million shares | Q2 2021: 51.96 million shares | Q3 2021: 52.59 million shares | Q1 2022: 56.50 million shares | Q2 2022: 58.62 million shares | Q3 2022: 60.57 million shares | Q1 2023: 80.64 million shares | Q2 2023: 93.81 million shares | Q3 2023: 95.10 million shares | Q1 2024: 108.76 million shares | Q2 2024: 110.58 million shares | Q3 2024: 124.43 million shares | Q1 2025: 128.94 million shares | Q2 2025: 129.82 million shares | Q3 2025: 130.03 million shares.
- Over the full 7 years of available data (2019 to 2025), Vaxcyte, Inc.'s Common Stock Shares Outstanding has grown by 3,128.1%.
- Historical annual values: Fiscal year 2025: 131.06 million shares | Fiscal year 2024: 124.89 million shares | Fiscal year 2023: 95.36 million shares | Fiscal year 2022: 79.47 million shares | Fiscal year 2021: 53.03 million shares | Fiscal year 2020: 51.07 million shares | Fiscal year 2019: 4.06 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: